Four bellwether trial dates are set for January 28, 2019; April 8, 2019, July 15, 2019, and November 4, 2019.
The bellwether cases are designed to be “representative” of most of the cases in the MDL. These cases will be used to set the tone for the rest of the litigations.
There are currently almost 2,000 product liability complaints pending against Sanofi-Aventis, each raising similar allegations that the drug maker failed to adequately warn about the risk of permanent hair loss linked to the side effects of Taxotere. Although hair loss is a known part of chemotherapy, claimants maintain they were given false and misleading information suggesting the hair regrows after discontinuing Taxotere. Plaintiffs indicate that if warned about the risk of permanent hair loss, they would have elected other forms of treatment.
Those who have been left with permanent hair loss from Taxotere are understandably outraged. Led to believe their hair would grow back, thousands of individuals have been left with patchy or clumpy hair, or with permanent baldness. Taxotere hair loss is a physical condition that results in negative body image, distress, and depression.